Neuroregenerative and neuroprotective actions of neuroimmunophilin compounds in traumatic and inflammatory neuropathies

Neurological Research

Volumn 26, Issue 4, 2004, Pages 371-380

  Gold, Bruce G ^a   Udina, Esther ^d   Bourdette, Dennis ^b,c   Navarro, Xavier ^d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

^d INSTITUT DE NEUROCIÈNCIES   (Spain)

Author keywords

FK506; FKBP; Immunosuppressant; Inflammatory; Nerve regeneration; Neuroprotection; Sciatic nerve

Indexed keywords

1 (3,3 DIMETHYL 1,2 DIOXOPENTYL) 2 PYRROLIDINECARBOXYLIC ACID 3 (3 PYRIDYL)PROPYL ESTER; DRUG DERIVATIVE; FK 506 BINDING PROTEIN; IMMUNOPHILIN; IMMUNOSUPPRESSIVE AGENT; NEUROIMMUNOPHILIN; TACROLIMUS; UNCLASSIFIED DRUG; V 10367;

DRUG ACTIVITY; DRUG INDICATION; DRUG MECHANISM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; NERVE CRUSH; NERVE GRAFT; NERVE GROWTH; NERVE INJURY; NERVE REGENERATION; NERVE TRANSECTION; NEUROPATHY; NEUROPROTECTION; NONHUMAN; PERIPHERAL NERVE INJURY; REVIEW; SCIATIC NERVE;

EID: 2942565668     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164104225013734     Document Type: Review

References (119)

1. Kino T, Hatanaka H, Hashimoto M, Nishiyama H. FK-506, a novel immunosuppressant isolated from a streptomyces. I. Fermentation, isolation, and physio-chemical and biological characteristics. J Antibiot 1987; 40: 1249-1255
2. Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot 1987; 40: 1256-1265
3. Hoffman AL, Makowka L, Banner B, et al. The use of FK-506 for small intestine allotransplantation: Inhibition of acute rejection and prevention of fatal graft-versus-host disease. Transplantation 1990; 49: 483-490
4. Starzl TE, Makowka L, Todo S. FK-506: A potential breakthrough in immunosuppression. Transplant Proc 1987; 19: S3-S104
5. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A. FK-506 for liver, kidney, and pancreas transplantation. Lancet 1989; 2: 1000-1004
6. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13: 136-142
7. Snyder SH, Lai MM, Burnett PE. Immunophilins in the nervous system. Neuron 1998; 21: 283-294
8. Gold BG. FK506 and the role of the immunophilin FKBP-52 in nerve regeneration. Drug Metab Rev 1999; 31: 649-663
9. Schreiber SL. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991; 251: 283-287
10. Alnemri ES, Fernandes-Alnemri T, Nelki DS, Dudley K, DuBois GC, Litwack G. Overexpression, characterization, and purification of a recombinant mouse immunophilin FKBP-52 and identification of an associated phosphoprotein. Proc Natl Acad Sci USA 1993; 90: 6839-6843
11. Sigal NH, Dumont FJ. Cyclosporin A, FK-506, and Rapamycin: Pharmacologic probes of lymphocyte signal transduction. Ann Rev Immunol 1992; 10: 519-560
12. Freman DA, Klee CB, Bierer BE, Burakoff SJ. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyclosporin A. Proc Natl Acad Sci USA 1992; 89: 3686-3690
13. Dumont FJ, Staruch MJ, Koprak SL, et al. The immunosuppressive and toxic effects of FK-506 are mechanistically related: Pharmacology of a novel antagonist of FK-506 and rapamycin. J Exp Med 1992; 176: 751-760
14. Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807-815
15. Walsh CT, Zydowsky LD, McKeon FD. Cyclosporin A, the cyclophilin class of peptidylprolyl isomerases, and blockade of T cell signal transduction. J Biol Chem 1992; 267: 13115-13118
16. Terada N, Or R, Weinberg K, Domenico J, Lucas JJ, Gelfand EW. Transcription of IL-4 genes is not inhibited by cyclosporin A in competent T cells. J Biol Chem 1992; 267: 21207-21210
17. Tocci MJ, Matkovich DA, Matkovich K, et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 1989; 143: 718-726
18. Lyons WE, Steiner JP, Snyder SH, Dawson TM. Neuronal regeneration enhances the expression of the immunophilin FKBP-12. J Neurosci 1995; 15: 2985-2994
19. Steiner JP, Dawson TM, Fotuhi M, et al. The immunosuppressant FK-506 enhances phosphorylation of GAP43: Implications for a role in modulation of growth cone function and neurotransmitter release. Soc Neurosci Abstr 1992; 603
20. Gold BG, Storm-Dickerson T, Austin DR. The immunosuppressant FK506 increases functional recovery and nerve regeneration following peripheral nerve injury. Restor Neurol Neurosci 1994; 6: 287-296
21. Lyons WE, George EB, Dawson TM, Steiner JP, Snyder SH. Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory ganglia. Proc Natl Acad Sci USA 1994; 91: 3191-3195
22. Shapiro R, Fung JJ, Jain AB, Parks P, Todo S, Starzl TE. The side effects of FK506 in humans. Transplant Proc 1990; 22: 35-36
23. Gold BG, Katoh K, Storm-Dickerson T. The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerve. J Neurosci 1995; 15: 7509-7516
24. Wang MS, Zeleny-Pooley M, Gold BG. Comparative dose-dependence study of FK506 and cyclosporin A on the rate of axonal regeneration in rat sciatic nerve. J Pharmacol Exp Ther 1997; 282: 1084-1093
25. Gold BG, Zeleny-Pooley M, Wang M-S, Chaturvedi P, Armistead DM. A non-immunosuppressant FKBP-12 ligand increases nerve regeneration. Exp Neurol 1997; 147: 269-278
26. Gold BG, Zeleny-Pooley M, Chaturvedi P, Wang M-S. Oral administration of a non-immunosuppressant FKBP-12 ligand speeds nerve regeneration. Neuroreport 1998; 9: 553-558
27. Steiner JP, Connolly MA, Valentine HL, et al. Neurotrophic actions of non-immunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. Nat Med 1997; 3: 421-428
28. Doolabh VB, Mackinnon SE. FK506 accelerates functional recovery following nerve grafting in a rat model. Plast Reconstr Surg 1999; 103: 1928-1936
29. Archibald SJ, Wang M-S, Gold BG. FK506 accelerates axonal regeneration through an artificial nerve guide in the rat sciatic nerve transection model. J Peripheral Nerv Syst 1999; 4: 202
30. Madsen JR, MacDonald P, Irwin N, et al. Tacrolimus (FK506) increases neuronal expression of GAP-43 and improves functional recovery after spinal cord injury in rats. Exp Neurol 1998; 154: 673-683
31. Bavetta S, Hamlyn PJ, Burnstock G, Lieberman AR, Anderson PN. The effects of FK506 on dorsal column axons following spinal cord injury in adult rats: neuroprotection and local regeneration. Exp Neurol 1999; 158: 382-393
32. Wang M-S, Gold BG. FK506 increases the regeneration of spinal cord axons in a predegenerated peripheral nerve autograft. J Spinal Cord Med 1999; 22: 287-296
33. Sugawara T, Itoh Y, Mizoi K. Immunosuppressants promote adult dorsal root regeneration into the spinal cord. Neuroreport 1999; 10: 3949-3953
34. Steiner JP, Hamilton GS, Ross DT, et al. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc Natl Acad Sci USA 1997; 94: 2019-2024
35. Gold BG, Gordon HS, Zeleny-Pooley M, Wang MS. FK506 produces regeneration, but not neuroprotection, of nigrostriatal dopaminergic neurons in MPTP-treated mice. Brain Pathol 1998; 8: 583
36. Costantini LC, Chaturvedi P, Armistead DM, McCaffrey PG, Deacon TW, Isacson O. A novel immunophilin ligand: Distinct branching effects on dopaminergic neurons in culture and neurotrophic actions after oral administration in an animal model of Parkinson's disease. Neurobiol Dis 1998; 5: 97-106
37. Emborg ME, Shin P, Roitberg B, et al. Systemic administration of the immunophilin ligand GPI 1046 in MPTP-treated monkeys. Exp Neurol 2001; 168: 171-182
38. Zhang C, Steiner JP, Hamilton GS, Hicks TP, Poulter MO. Regeneration of dopaminergic function in 6-hydroxydopamine-lesioned rats by neuroimmunophilin ligand treatment. J Neurosci 2001; 21: 1-6
39. Gold BG. Neuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders. Exp Opinion Invest Drugs 2000; 9: 2331-2342
40. Guo X, Dillman III JF, Dawson VL, Dawson TM. Neuroimmunophilins: novel neuroprotective and neuroregenerative targets. Ann Neurol 2001; 50: 6-16
41. Dubernard J-M, Owen E., Herzberg G, et al. Human hand allograft: report on first 6 months. Lancet 1999; 353: 1315-1320
42. Jones JW, Gruber SA, Barker JH, Breidenbach WC. Successful hand transplantation: One year follow-up. N Engl J Med 2000; 343: 468-473
43. Pei G, Gu L, Yu L. A preliminary report of two cases of human hand allograft. Zhonghua Yi Xue Za Zhi 2000; 80: 417-421
44. Guilford Pharmaceutical Inc. Guilford Pharmaceuticals announces completion of NIL-A phase II clinical trial for Parkinson's disease. Press Release. Available at: http://www.corporate-ir.net/ ireye/ir_site.zhtml?ticker= GLFD&script=410&layout=-6 &item_id=195083 26 July 2001, date last accessed
45. Gold BG, Storm-Dickerson T, Austin DR, Katoh K. FK506, an immunosuppressant, increases functional recovery and axonal regeneration in the rat following axotomy of the sciatic nerve. Soc Neurosci Abstr 1993; 19: 1316
46. Gold BG, Gordon HS, Wang M-S. Efficacy of delayed or discontinuous FK506 administrations on nerve regeneration in the rat sciatic nerve crush model: lack of evidence for a conditioning lesion-like effect. Neurosci Lett 1999; 267: 33-36
47. Hamilton GS. Immunophilin ligands for the treatment of neurological disorders. Exp Opin Ther Patents 1998; 8: 1109-1124
48. Revill WP, Voda J, Reeves CR, et al. Genetically engineered analogs of ascomycin for nerve regeneration. J Pharmacol Exp Therap 2002; 302: 1278-1285
49. Udina E, Ceballos D, Verdu E, Gold BG, Navarro X. Bimodal dose-dependence of FK506 on the rate of axonal regeneration in mouse peripheral nerve. Muscle Nerve 2002; 26: 348-355
50. Gold BG. Neuroimmunophilin ligands and the role of steroid hormone chaperone proteins in nerve regeneration. In: Gold BG, Fischer G, Herdegen T, eds, Immunophilins in the brain. FKBP-ligands: Novel strategies for the treatment of neurodegenerative disorders, Barcelona: Prous Science, 2000: pp 3-22
51. r 90,000 heat shock protein: Main structural features of a mammalian p59 protein. Proc Natl Acad Sci USA 1992; 89: 6270-6274
52. Lee M, Doolabh VB, Mackinnon SE, Jost S. FK506 promotes functional recovery in crushed rat sciatic nerve. Muscle Nerve 2000; 23: 633-640
53. Fansa H, Keilhoff G, Horn T, Altmann S, Wolf G, Schneider W. Stimulation of Schwann cell proliferation and axonal regeneration by FK 506. Restor Neurol Neurosci 2000; 16: 77-86
54. Navarro X, Udina E, Ceballos D, Gold BG. Effects of FK506 on nerve regeneration and reinnervation after graft or tube repair of long nerve gaps. Muscle Nerve 2001; 24: 905-915
55. Fansa H, Keilhoff G, Altmann S, Plogmeier K, Wolf G, Schneider W. The effect of the immunosuppressant FK 506 on peripheral nerve regeneration following nerve grafting. J Hand Surg [Br] 1999; 24: 38-427
56. Udina E, Voda J, Gold BG, Navarro X. Comparative dose-dependence study of FK506 on transected mouse sciatic nerve repaired by allograft or xenograft. J Peripher Nerv Syst 2003; 8: 145-154
57. Udina E, Gold BG, Navarro X. Comparison of continuous and discontinuous FK506 administrations of autograft or allograft repair of sciatic nerve resection. Muscle Nerve 2004; in press
58. Grand AG, Myckatyn TM, Mackinnon SE, Hunter DA. Axonal regeneration after cold preservation of nerve allografts and immunosuppression with tacrolimus in mice. J Neurosurg 2002; 96: 924-932
59. Höke A, Gordon T, Zochodne DW, Sulaiman OA. A decline in glial cell-line-derived neurotrophic factor expression is associated with impaired regeneration after long-term Schwann cell denervation. Exp Neurol 2002; 173: 77-85
60. Pollard JD, Fitzpatrick L. An ultrastructural comparison of peripheral nerve allografts and autografts. Acta Neuropathol (Berl) 1973; 23: 152-165
61. Zalewski AA, Gulati AK. Failure of cyclosporin-A to induce immunological unresponsiveness to nerve allografts. Exp Neurol 1984; 83: 659-663
62. Ansselin AD, Pollard JD, Davey DF. Immunosuppression in nerve allografting: is it desirable? J Neurol Sci 1992; 112: 160-169
63. Margreiter R, Brandacher G, Ninkovic M, Steurer W, Kreczy A, Schneeberger S. A double-hand transplant can be worth the effort! Transplantation 2002; 74: 85-90
64. Feng FY, Ogden MA, Myckatyn TM, Grand AG, Jensen JN, Hunter DA, Mackinnon SE. FK506 rescues peripheral nerve allografts in acute rejection. J Neurotrauma 2001; 18: 217-229
65. Büttemeyer R, Rao U, Jones NF. Peripheral nerve allograft transplantation with FK506: Functional, histological, and immunological results before and after discontinuation of immunosuppression. Ann Plast Surg 1995; 35: 396-401
66. Okajima S, Hojo T, Tamai K, Takai S, Hirasawa Y. Histological and electrophysiological analysis of the peripheral nerve allografts using an immunosuppressive agent. Microsc Res Tech 2002; 58: 52-58
67. Sakai K, Date I, Yoshimoto Y, et al. The effect of a new immunosuppressive agent, FK-506, on xenogenic neural transplantation in rodents. Brain Res 1991; 565: 167-170
68. Butí M, Verdú E, Labrador RO, Vilches JJ, Forés J, Navarro X. Influence of physical parameters of nerve chambers on peripheral nerve regeneration and reinnervation. Exp Neurol 1996; 137: 26-33
69. Rodríguez FJ, Gómez N, Labrador RO, Butí M, Ceballos D, Cuadras J, Verdú E, Navarro X. Improvement of regeneration with predegenerated nerve transplants in silicone chambers. Restor Neurol Neurosci 1999; 14: 65-79
70. Lundborg G, Dahlin LB, Danielsen N, etal. Nerve regeneration in silicone chambers: influence of gap length and of distal stump components. Exp Neurol 1982; 76: 361-375
71. Williams LR, Longo FM, Powell HC, Lundborg G, Varon S. Spatial-temporal progress of peripheral nerve regeneration within a silicone chamber: parameters for a bioassay. J Comp Neurol 1983; 218: 460-470
72. Navarro X, Verdu E, Buti M. Comparison of regenerative and reinnervating capabilities of different functional types of nerve fibers. Exp Neurol 1994; 129: 217-224
73. Verdú E, Navarro X. Comparison of immunohistochemical and functional reinnervation of skin and muscle after peripheral nerve injury. Exp Neurol 1997; 146: 187-198
74. Udina E, Ceballos D, Gold BG, Navarro X. FK506 enhances reinnervation by regeneration and by collateral sprouting of peripheral nerve fibers. Exp Neurol 2003; 183: 220-231
75. Sezen SF, Hoke A, Burnett AL, Snyder SH. Immunophilin ligand FK506 is neuroprotective for penile innervation. Nat Med 2001; 7: 1073-1074
76. Keswani SC, Chander B, Hasan C, Griffin JW, McArthur JC, Hoke A. FK506 is neuroprotective in a model of antiretroviral toxic neuropathy. Ann Neurol 2003; 53: 57-64
77. Gold BG, Voda J, Gordon H. The immunosuppressant FK506 elicits a neuronal heat shock response and protects against acrylamide neuropathy. Exp Neurol 2004; in press
78. Hahn AF. Guillain-Barre syndrome. Lancet 1998; 352: 635-641
79. Hughes RA, Hadden RD, Gregson NA, Smith KJ. Pathogenesis of Guillain-Barre syndrome. J Neuroimmunol 1999; 100: 74-97
80. Asbury AK. New concepts of Guillain-Barre syndrome. J Child Neurol 2000; 15: 183-191
81. Winer JB. Guillain Barre syndrome. Mol Pathol 2001; 54: 381-385
82. Maurer M, Gold R. Animal models of immune-mediated neuropathies. Curr Opin Neurol 2002; 15: 617-622
83. Hughes RA. Systematic reviews of treatment for inflammatory demyelinating neuropathy. J Anat 2002; 200: 331-339
84. Adachi A, Araga S, Takahashi K. Immunosuppressive effect of FK506 on experimental allergic neuritis in Lewis rats: change of T cell subsets. Intern Med 1992; 31: 6-10
85. Ahlmen J, Andersen O, Hallgren G, Peilot B. Positive effects of tacrolimus in a case of CIDP. Transplant Proc 1998; 30: 4194
86. Gold BG, Densmore V, Shou W, Matzuk MM, Gordon HS. Immunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506. J Pharmacol Exp Ther 1999; 289: 1202-1210
87. r of 63,000, 56,000, and 50,000. J Biol Chem 1991; 266: 6708-6713
88. Sánchez ER. Hsp56: A novel heat shock protein associated with untransformed steroid receptor complexes. J Biol Chem 1990; 265: 22067-22070
89. Tai P-KK, Albers MW, Chang H, Faber LE, Schreiber SL. Association of a 59-kilodalton immunophilin with the glucocorticoid receptor complex. Science 1992; 256: 1315-1318
90. Bermingham NA, Rauf S, Katsanis N, Martin JE, Hunter AJ, Fisher EMC. The immunophilin FKBP4 (FKBP52/FKBP59) maps to the distal short arm of human chromosome 12. Mamm Genome 1998; 9: 268
91. Owens-Grillo JK, Czar MJ, Hutchison KA, Hoffmann K, Perdew GH, Pratt WB. A model of protein targeting mediated by mmunophilins and other proteins that bind to hsp90 via tetratricopeptide repeat domains. J Biol Chem 1996; 271: 13468-13475
92. Czar MJ, Owens-Grillo JK, Yem AW, et al. The hsp56 immunophilin component of untransformed steroid receptor complexes is localized both to microtubules in the cytoplasm and to the same nonrandom regions within the nucleus as the steroid receptor. Mol Endocrin 1994; 8: 1731-1741
93. Lebeau MC, Massol N, Herrick J, Faber LE, Renoin MJ, Radanyi C, Baulieu EE. P59, an hsp 90-binding protein. Cloning and sequencing of its cDNA and preparation of a peptide-directed polyclonal antibody. J Biol Chem 1992; 267: 4281-4284
94. Owens-Grillo JK, Hoffmann K, Hutchison KA, et al. The cyclosporin A-binding immunophilin CyP-40 and the FK506-binding immunophilin hsp56 bind to a common site on hsp90 and exist in independent cytosolic heterocomplexes with the untransformed glucocorticoid receptor. J Biol Chem 1995; 270: 20479-20484
95. Drengler SM, Handa RJ, Jones KJ. Effects of axotomy and testosterone on androgen receptor mRNA expression in hamster facial motoneurons. Exp Neurol 1997; 146: 374-379
96. Kujawa KA, Emeric E, Jones KJ. Testosterone differentially regulates the regenerative properties of injured hamster facial motoneurons. J Neurosci 1991; 11: 3898-3906
97. Kujawa KA, Jacob JM, Jones KJ. Testosterone regulation of the regenerative properties of injured rat sciatic motor neurons. J Neurosci Res 1993; 35: 268-273
98. Lustig RH, Hua P, Smith LS, Wang C, Chang C. An in vitro model for the effects of androgen on neurons employing androgen receptor-transfected PC12 cells. Mol Cell Neurosci 1994; 5: 587-596
99. Yu WA, Srinivasan R. Effect of testosterone and 5α- dihydrotestosterone on regeneration of the hypoglossal nerve in rats. Exp Neurol 1981; 71: 431-435
100. Ferreria A, Caceres A. Estrogen-enhanced neurite growth: Evidence for a selective induction of tau and stable microtubules. J Neurosci 1991; 11: 392-400
101. Gollapudi L, Oblinger MM. Increased expression of estrogen receptor in PC12 cells: Effects on neurite outgrowth. Soc Neurosci Abstr 1997; 23: 343
102. Lustig RH, Hua P, Yu W, Ahmad FJ, Bass PW. An in vitro model for the effects of estrogen on neurons employing estrogen receptor-transfected PC12 cells. J Neurosci 1994; 14: 3945-3957
103. Ma ZQ, Spreafico E, Pollio G, Santagati S, Conti E, Cattaneo E. Activated estrogen receptor mediates growth arrest and differentiation of a neuroblastoma cell line. Proc Natl Acad Sci USA 1993; 90: 3740-3744
104. Sano M, Yoshida M, Fukui S, Kitajima S. Radicicol potentiates neurotrophin-mediated neurite outgrowth and survival of cultured sensory neurons from chick embryo. J Neurochem 1999; 72: 2256-2263
105. Pratt WB. The hsp90-based chaperone system: Involvement in signal transduction from a variety of hormone and growth factor receptors. Proc Soc Exp Biol Med 1998; 217: 420-434
106. Gold BG, Villafranca JE. Neuroimmunophilin ligands: the development of novel neuroregenerative/neuroprotective compounds. Curr Top Med Chem 2003; 3: 1368-1375
107. Gold BG, Zhong YP. FK506 requires stimulation of the extracellular signal regulated kinase 1/2 and the steroid receptor chaperone protein p23 for neurite elongation. Neurosignals 2004; 13: 122-129
108. Volonte C, Angelastro JM, Greene LA. Association of protein kinases ERK1 and ERK2 with p75 nerve growth factor receptors. J Biol Chem 1993; 268: 21410-21415
109. York RD, Yao H, Dillon T, et al. Rapl mediates sustained MAP kinase activation induced by nerve growth factor. Nature 1998; 392: 622-626
110. Tsuji M, Inanami O, Kuwabara M. Induction of neurite outgrowth in PC12 cells by α-phenyl-N-tert-butylnitron through activation of protein kinase C and the ras-extracellular signal-regulated kinase pathway. J Biol Chem 2001; 276: 32779-32785
111. Boglári G, Szeberényi J. Nerve growth factor in combination with second messenger analogues causes neuronal differentiation of PC12 cells expressing a dominant inhibitory Ras protein without inducing activation of extracellular signal-regulated kinases. Eur J Neurosci 2001; 14: 1445-1454
112. Averill S, Delcroix JD, Michael GJ, Tomlinson DR, Fernyhough P, Priestley JV. Nerve growth factor modulates the activation status and fast axonal transport of ERK 1/2 in adult nociceptive neurones. Mol Cell Neurosci 2001; 18: 183-196
113. Aletsee C, Beros A, Mullen L, et al. Ras/MEK but not p38 signaling mediates NT-3-induced neurite extension from spiral ganglion neurons. J Ass Res Otolaryngol 2001; 2: 377-387
114. Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 2000; 10: 381-391
115. Macleod MR, Allsopp TE, McLuckie J, Kelly JS. Serum withdrawal causes apoptosis in SHSY 5Y cells. Brain Res 2001; 889: 308-315
116. Guo X, Dawson VL, Dawson TM. Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons. Eur J Neurosci 2001; 13: 1683-1693
117. Kaibori M, Inoue T, Tu W, et al. FK506, but not cyclosporin A, prevents mitochondrial dysfunction during hypoxia in rat hepatocytes. Life Sci 2001; 69: 17-26
118. Klettner A, Herdegen T. The immunophilin-ligands FK506 and V-10,367 mediate neuroprotection by the heat shock response. Br J Pharmacol 2003; 138: 1004-1012
119. Lu A, Ran R, Parmentier-Batteur S, Nee A, Sharp FR. Geldanamycin induces heat shock proteins in brain and protects against focal cerebral ischemia. J Neurochem 2002; 81: 355-364